Real-world comparison of GLP-1 agonists and SGLT2 inhibitors seeks optimal T2D cardiovascular outcomes
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Abstract
This study aims to directly compare GLP-1 agonists and SGLT2 inhibitors for cardiovascular and other patient-important outcomes in type 2 diabetes.